Banque Pictet & Cie SA Purchases Shares of 15,348 Abivax SA Sponsored ADR $ABVX

Banque Pictet & Cie SA purchased a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 15,348 shares of the company’s stock, valued at approximately $2,070,000.

Several other hedge funds have also recently modified their holdings of the stock. EverSource Wealth Advisors LLC raised its position in shares of Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after purchasing an additional 369 shares during the last quarter. First Horizon Corp purchased a new stake in Abivax during the 3rd quarter worth approximately $36,000. Union Bancaire Privee UBP SA acquired a new position in Abivax during the 4th quarter valued at approximately $67,000. Hantz Financial Services Inc. acquired a new position in Abivax during the 3rd quarter valued at approximately $52,000. Finally, Gordian Capital Singapore Pte Ltd purchased a new position in shares of Abivax in the third quarter worth $76,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Trading Up 3.0%

Shares of NASDAQ:ABVX opened at $118.37 on Friday. Abivax SA Sponsored ADR has a 12-month low of $4.77 and a 12-month high of $148.83. The business has a 50 day moving average of $117.72 and a two-hundred day moving average of $111.69. The company has a market capitalization of $9.37 billion, a PE ratio of -22.04 and a beta of 1.68.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($1.20) EPS for the quarter. The firm had revenue of $0.52 million for the quarter. Equities research analysts predict that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. BTIG Research reissued a “buy” rating and set a $150.00 price objective on shares of Abivax in a report on Wednesday, February 25th. Piper Sandler restated an “overweight” rating and issued a $142.00 target price on shares of Abivax in a research note on Tuesday, December 16th. Wedbush assumed coverage on Abivax in a research report on Tuesday, February 24th. They set an “outperform” rating and a $110.00 price target for the company. Guggenheim reissued a “buy” rating and issued a $175.00 price objective on shares of Abivax in a report on Thursday, December 18th. Finally, Barclays raised their price objective on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $137.15.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.